Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 5, 2005, Pages 944-947

  Wootton, Mandy ^a,b   Bennett, Peter M ^a   MacGowan, Alasdair P ^b   Walsh, Timothy R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Antibiotic resistance; Cell wall; Mechanism of resistance

Indexed keywords

AUTOLYSIN; GLYCOPEPTIDE; LYSOSTAPHIN; TRITON X 100;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOLYSIS; BACTERIAL CELL WALL; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIOLYSIS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION; GLYCOPEPTIDES; HUMANS; LYSOSTAPHIN; MICROBIAL SENSITIVITY TESTS; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; OCTOXYNOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, MESSENGER; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 27744482600     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki289     Document Type: Article

References (9)

1. Boyle-Vavra S, Challapalli M, Daum RS. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother 2003; 47: 2036-9.
2. Koehl JL, Muthaiyan A, Jayaswal RK et al. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 3749-57.
3. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
4. Sugai M, Fujiwara T, Ohta K et al. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus aureus and Staphylococcus capitis. J Bacteriol 1997; 179: 4311-8.
5. Komatsuzawa H, Ohta K, Yamada S et al. Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother 2002; 46: 75-81.
6. Boyle-Vavra S, Labischinski H, Ebert CC et al. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate-resistant clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 2001; 45: 280-7.
7. Boyle-Vavra S, Carey RB, Daum RS. Development of lysostaphin and vancomycin resistance in pre-GISA vancomycin tolerant, methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2001; 48: 617-25.
8. Wootton M, Avison MB, Howe RA et al. Genetic analysis of seventeen genes in vancomycin intermediate Staphylococcus aureus (VISA) and hetero(h)VISA phenotype. J Antimicrob Chemother 2004; 53: 406-7.
9. Shaw LN, Golonka E, Szmyd G et al. Cytoplasmic control of premature activation of a secreted protease zymogen: Deletion of staphostatin B (SspC) in Staphylococcus aureus 8325-4 yeilds a profound pleitropic phenotype. J Bacteriol 2005; 187: 1751-62.